deltatrials
Completed PHASE2 NCT00003465

Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal

Sponsor: Duke University

Conditions Brain and Central Nervous System Tumors
Interventions temozolomide
Updated 5 times since 2017 Last updated: Jun 19, 2013 Started: Mar 31, 1998 Completion: Feb 28, 2001

This PHASE2 trial investigates Brain and Central Nervous System Tumors and is currently completed. Duke University leads this study, which shows 5 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • National Cancer Institute (NCI)
Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States